Australia
Reimbursed Care Access
Australia permits limited, regulated medical access to certain psychedelic compounds while most remain prohibited outside of research. Psilocybin and MDMA were rescheduled (effective 1 July 2023) to allow prescribing by TGA‑authorised psychiatrists for narrow indications; esketamine (Spravato) is TGA‑approved and, as of 1 May 2025, has a PBS listing for treatment‑resistant depression. Other classical and novel psychedelics (DMT, 5‑MeO‑DMT, ibogaine, mescaline, 2C‑X, and ayahuasca preparations) remain controlled/schedule 9 or otherwise illegal except within approved clinical trials or very restricted licensing regimes.
📜History of research in Australia
The history of psychedelic research in Australia tracks closely with the international trajectory: early laboratory discovery and clinical curiosity in the mid 20th century, widespread prohibition in the late 1960s and 1970s, a long period of marginalisation, and then a clinical and regulatory renaissance from the 2010s onwards. Seminal discoveries abroad – most notably Albert Hofmann's work at Sandoz and the company’s marketing of LSD (Delysid) to psychiatrists and researchers from the late 1940s – meant that Australian psychiatrists and researchers were exposed to and occasionally contributed to early clinical work with lysergamides and other serotonergic compounds. Throughout the 1950s and 1960s there were case reports and small clinical investigations in Australia consistent with contemporaneous international practice, but documentation is fragmented and much of that clinical activity was curtailed by the rapidly changing legal environment.
From the late 1960s into the 1970s, Australia tightened control of classical psychedelics in line with international treaties and national drug-control legislation. Substances such as LSD, psilocybin and later MDMA became controlled under the Poisons Standard and relevant state and territory drug laws, making routine clinical use unlawful outside very restricted research or authorised programs. This regulatory classification created a long lull in mainstream clinical research and clinical application through the 1980s and 1990s.
Beginning in the 2000s and accelerating in the 2010s, a global scientific renaissance in psychedelic-assisted therapies re-engaged Australian researchers and clinicians. Universities, independent research groups and philanthropic and industry stakeholders began sponsoring pilot studies, mechanistic neuroimaging work and early-phase clinical trials, primarily focusing on treatment-resistant mental health conditions. Over the last decade an ecosystem of academic centres, advocacy organisations and emerging biotechnology companies has built capacity for clinical trials, good manufacturing practice (GMP) supply, therapist training and regulatory engagement, setting the stage for authorised clinical access pathways that have started to appear in national policy discussions.
🔬Research Focus
Contemporary Australian psychedelic research places primary emphasis on clinical trials for treatment-resistant mood disorders, post-traumatic stress disorder (PTSD) and certain substance-use disorders. Psilocybin-assisted therapy has been the focus for depressive disorders and end-of-life distress, while MDMA-assisted therapy has chiefly been investigated for PTSD. There is also growing interest in translational and mechanistic studies using functional neuroimaging, electrophysiology and biomarkers to understand acute and long-term neural change associated with psychedelic-assisted interventions. Lesser but notable activity exists around DMT/ayahuasca, LSD and ketamine-related research, with ketamine occupying an adjacent but better established clinical niche.
In addition to clinical efficacy studies, Australian strengths include work on safety, service-delivery models, therapist training and regulatory frameworks. Several groups are examining pragmatic aspects of integration into mental-health services (for example models for outpatient delivery, risk management and patient selection), and there is active engagement on manufacturing, quality assurance and supply-chain issues for investigational medicinal products. Ethical, legal and cultural scholarship has also been important — especially work focused on culturally safe research practices and engagement with Aboriginal and Torres Strait Islander communities, recognising distinct ethical and social considerations in Australia’s diverse populations.
🏆Key Milestones
🚀Future Outlook
Over the next 12–24 months Australia is likely to see expansion of authorised clinical and research activity rather than a sudden, broad-based clinical rollout. Expect growth in phase II and phase III clinical trials at academic centres, an increasing number of authorised prescribers or special-access approvals in carefully regulated clinical programmes, and investment in GMP manufacture and local supply chains. Regulatory attention will concentrate on training and accreditation for therapists, risk-mitigation frameworks and integration pathways within existing mental-health services.
Policy and ethical discourse will continue to be prominent: regulators, professional colleges and Indigenous stakeholders are likely to finalise guidelines on culturally appropriate practice, informed consent and equitable access. Commercial and philanthropic investment is also expected to increase, supporting larger multi-site trials, comparative effectiveness research and health-economics evaluations to inform potential wider adoption contingent on demonstrated clinical effectiveness and system readiness.